Review



poly(i:c) (hmw) vaccigrade  (InvivoGen)


Bioz Verified Symbol InvivoGen is a verified supplier
Bioz Manufacturer Symbol InvivoGen manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 98
      Buy from Supplier

    Structured Review

    InvivoGen poly(i:c) (hmw) vaccigrade
    Poly(i:C) (Hmw) Vaccigrade, supplied by InvivoGen, used in various techniques. Bioz Stars score: 98/100, based on 3793 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vac+pic/Poly(I%3AC)+(HMW)+VacciGrade/custom%40vac-pic%4042536482
    Average 98 stars, based on 3793 article reviews
    poly(i:c) (hmw) vaccigrade - by Bioz Stars, 2026-09
    98/100 stars

    Images

    Related Articles

    Mouse Assay:

    Article Title: Viral Molecular Mimicry Influences the Antitumor Immune Response in Murine and Human Melanoma
    Article Snippet: .. Mice were vaccinated twice, and injections were performed at 1-week interval (days 0 and 7) at the base of the tail with 40 μg of peptides (10 μg each peptide) and 40 μg of adjuvant [VacciGrade poly(I:C), catalog no. vac-pic, Invivogen] in a final injectable volume of 100 μL. ..

    Article Title: Viral Molecular Mimicry Influences the Antitumor Immune Response in Murine and Human Melanoma
    Article Snippet: .. Mice were vaccinated twice, and injections were performed at 1-week interval (days 0 and 7) at the base of the tail with 40 mg of peptides (10 mg each peptide) and 40 mg of adjuvant [VacciGrade poly(I:C), catalog no. vac-pic, Invivogen] in a final injectable volume of 100 mL. ..

    Adjuvant:

    Article Title: Viral Molecular Mimicry Influences the Antitumor Immune Response in Murine and Human Melanoma
    Article Snippet: .. Mice were vaccinated twice, and injections were performed at 1-week interval (days 0 and 7) at the base of the tail with 40 μg of peptides (10 μg each peptide) and 40 μg of adjuvant [VacciGrade poly(I:C), catalog no. vac-pic, Invivogen] in a final injectable volume of 100 μL. ..

    Article Title: Viral Molecular Mimicry Influences the Antitumor Immune Response in Murine and Human Melanoma
    Article Snippet: .. Mice were vaccinated twice, and injections were performed at 1-week interval (days 0 and 7) at the base of the tail with 40 mg of peptides (10 mg each peptide) and 40 mg of adjuvant [VacciGrade poly(I:C), catalog no. vac-pic, Invivogen] in a final injectable volume of 100 mL. ..

    other:

    Article Title: Combining toll-like receptor agonists with immune checkpoint blockade affects antitumor vaccine efficacy.
    Article Snippet: TLR3 agonist (Poly(I:C) HMW, vac- pic) was purchased from InvivoGen (San Diego, CA).

    Positive Control:

    Article Title: Influenza vaccine composition based on novel nucleic acid
    Article Snippet: .. PolyIC (InvivoGen, Poly(I:C) (HMW) VacciGradeTM cat #, vac-pic) was used as a positive control. ..

    High Molecular Weight:

    Article Title: Local therapy with combination TLR agonists stimulates systemic anti-tumor immunity and sensitizes tumors to immune checkpoint blockade
    Article Snippet: .. Once established, right flank tumors were treated intratumorally (i.t.) with single or pairwise combination of vaccigrade TLR agonists: poly(I:C), high molecular weight (HMW), cat# VAC-PIC; Resiquimod (R848), cat# VAC-R848; CpG ODN 2395, cat# VAC-2395-1; monophosphoryl lipid A (MPLA), cat# VAC-MPLS, (all from InvivoGen), daily for 6 days. .. For combination of TLR agonists and ICB treatment, mice received three intraperitoneal (i.p.) injections of 200 μg anti-programmed cell death protein-1(PD-1) (BioXcell, Clone RMPI-14), every 2 days, starting on day 8 after tumor inoculation in addition to i.t. treatment with combination of TLR agonists.

    Article Title: Local therapy with combination TLR agonists stimulates systemic anti-tumor immunity and sensitizes tumors to immune checkpoint blockade
    Article Snippet: .. Once established, right flank tumors were treated intratumorally (i.t.) with single or pairwise combination of vaccigrade TLR agonists: poly(I:C), high molecular weight (HMW), cat# VAC-PIC; Resiquimod (R848), cat# VAC-R848; CpG ODN 2395, cat# VAC-2395-1; monophosphoryl lipid A (MPLA), cat# VAC-MPLS, (all from InvivoGen), daily for 6 days. .. For combination of TLR agonists and ICB treatment, mice received three intraperitoneal (i.p.) injections of 200 μg anti-programmed cell death protein-1(PD -1) (BioXcell, Clone RMPI-14), every 2 days, starting on day 8 after tumor inoculation in addition to i.t. treatment with combination of TLR agonists.



    Similar Products

    poly(i:c) (hmw) vaccigrade  (InvivoGen)
    98
    InvivoGen poly(i:c) (hmw) vaccigrade
    Poly(i:C) (Hmw) Vaccigrade, supplied by InvivoGen, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vac+pic/Poly(I%3AC)+(HMW)+VacciGrade/custom%40vac-pic%4042536482
    Average 98 stars, based on 1 article reviews
    poly(i:c) (hmw) vaccigrade - by Bioz Stars, 2026-09
    98/100 stars
    		  Buy from Supplier
    poly i c hmw vaccigradetm  (InvivoGen)
    96
    InvivoGen poly i c hmw vaccigradetm
    Poly I C Hmw Vaccigradetm, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vac+pic/Poly(I%3AC)+(HMW)+VacciGrade/bio_rxiv__64898__2026__05__13__724871-146-0-6
    Average 96 stars, based on 1 article reviews
    poly i c hmw vaccigradetm - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    i c pic  (InvivoGen)
    96
    InvivoGen i c pic
    I C Pic, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vac+pic/Poly(I%3AC)+(HMW)+VacciGrade/pm41974867-220-12-15
    Average 96 stars, based on 1 article reviews
    i c pic - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    tlr3 ligand  (InvivoGen)
    96
    InvivoGen tlr3 ligand
    In vivo or in vitro treatment with pDNA-LNP increased IFN-I release (A) Mice were treated as in B with PBS or 30μg of mRNA-LNP, pDNA, or pDNA-LNP. Sera were collected on day 12 and assessed for IFN-β concentration by ELISA. (B) Splenocytes from wild-type mice were incubated with media alone, a pool of Toll-like receptor agonists <t>(TLR3,</t> TLR7, and TLR9 agonists as positive control), or 1 μg per well of mRNA, mRNA-LNP, pDNA, or pDNA-LNP for 48 h. Supernatants were assessed for IFN-β by ELISA. (C) Splenocytes from wild-type mice were incubated with media alone or 1 μg per well of mRNA, mRNA-LNP, pDNA, or pDNA-LNP for 48 h. Supernatants were assessed by Luminex for CXCL10 and CCL7. (A and B) N = 3 mice per group. (C) Data are technical replicates from one mouse per group. ∗ p < 0.05 and ∗∗ p < 0.01 as assessed by one-way ANOVA with Tukey’s correction for multiple comparisons. Error bars represent mean ± SD. Experiment in (B and C) is representative of one other independent experiment.
    Tlr3 Ligand, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vac+pic/Poly(I%3AC)+(HMW)+VacciGrade/pmc13148951-215-10-14
    Average 96 stars, based on 1 article reviews
    tlr3 ligand - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    i c  (InvivoGen)
    96
    InvivoGen i c
    In vivo or in vitro treatment with pDNA-LNP increased IFN-I release (A) Mice were treated as in B with PBS or 30μg of mRNA-LNP, pDNA, or pDNA-LNP. Sera were collected on day 12 and assessed for IFN-β concentration by ELISA. (B) Splenocytes from wild-type mice were incubated with media alone, a pool of Toll-like receptor agonists <t>(TLR3,</t> TLR7, and TLR9 agonists as positive control), or 1 μg per well of mRNA, mRNA-LNP, pDNA, or pDNA-LNP for 48 h. Supernatants were assessed for IFN-β by ELISA. (C) Splenocytes from wild-type mice were incubated with media alone or 1 μg per well of mRNA, mRNA-LNP, pDNA, or pDNA-LNP for 48 h. Supernatants were assessed by Luminex for CXCL10 and CCL7. (A and B) N = 3 mice per group. (C) Data are technical replicates from one mouse per group. ∗ p < 0.05 and ∗∗ p < 0.01 as assessed by one-way ANOVA with Tukey’s correction for multiple comparisons. Error bars represent mean ± SD. Experiment in (B and C) is representative of one other independent experiment.
    I C, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vac+pic/Poly(I%3AC)+(HMW)+VacciGrade/pmc12909587-95-12-13
    Average 96 stars, based on 1 article reviews
    i c - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    In vivo or in vitro treatment with pDNA-LNP increased IFN-I release (A) Mice were treated as in B with PBS or 30μg of mRNA-LNP, pDNA, or pDNA-LNP. Sera were collected on day 12 and assessed for IFN-β concentration by ELISA. (B) Splenocytes from wild-type mice were incubated with media alone, a pool of Toll-like receptor agonists (TLR3, TLR7, and TLR9 agonists as positive control), or 1 μg per well of mRNA, mRNA-LNP, pDNA, or pDNA-LNP for 48 h. Supernatants were assessed for IFN-β by ELISA. (C) Splenocytes from wild-type mice were incubated with media alone or 1 μg per well of mRNA, mRNA-LNP, pDNA, or pDNA-LNP for 48 h. Supernatants were assessed by Luminex for CXCL10 and CCL7. (A and B) N = 3 mice per group. (C) Data are technical replicates from one mouse per group. ∗ p < 0.05 and ∗∗ p < 0.01 as assessed by one-way ANOVA with Tukey’s correction for multiple comparisons. Error bars represent mean ± SD. Experiment in (B and C) is representative of one other independent experiment.

    Journal: Molecular Therapy Advances

    Article Title: Plasmid DNA vaccines encapsulated in lipid nanoparticles elicit STING-dependent type 1 interferon release

    doi: 10.1016/j.omta.2026.201698

    Figure Lengend Snippet: In vivo or in vitro treatment with pDNA-LNP increased IFN-I release (A) Mice were treated as in B with PBS or 30μg of mRNA-LNP, pDNA, or pDNA-LNP. Sera were collected on day 12 and assessed for IFN-β concentration by ELISA. (B) Splenocytes from wild-type mice were incubated with media alone, a pool of Toll-like receptor agonists (TLR3, TLR7, and TLR9 agonists as positive control), or 1 μg per well of mRNA, mRNA-LNP, pDNA, or pDNA-LNP for 48 h. Supernatants were assessed for IFN-β by ELISA. (C) Splenocytes from wild-type mice were incubated with media alone or 1 μg per well of mRNA, mRNA-LNP, pDNA, or pDNA-LNP for 48 h. Supernatants were assessed by Luminex for CXCL10 and CCL7. (A and B) N = 3 mice per group. (C) Data are technical replicates from one mouse per group. ∗ p < 0.05 and ∗∗ p < 0.01 as assessed by one-way ANOVA with Tukey’s correction for multiple comparisons. Error bars represent mean ± SD. Experiment in (B and C) is representative of one other independent experiment.

    Article Snippet: In some cases, cells were also incubated with 10 μg/mL TLR3 ligand (poly I:C, InVivoGen #vac-pic, San Diego, CA), 3 μg/mL TLR7 ligand (Gardiquimod, InVivoGen #tlrl-gdqs-1), 5 μM TLR9 ligand (ODN1826, Integrated DNA Technologies, San Diego, CA), 0.5 μM STING agonist (diABZI, InVivoGen #tlrl-diabzi-2; a generous gift from Dr.

    Techniques: In Vivo, In Vitro, Concentration Assay, Enzyme-linked Immunosorbent Assay, Incubation, Positive Control, Luminex

    Increased IFN-β levels were not due to TLR3, 7, or 9 signaling but were at least partially mediated by STING signaling (A) Splenocytes from wild-type, TLR3 knockout (TLR3KO), TLR7KO, or TLR9KO were incubated with indicated TLR ligands or 1 μg per well of mRNA-LNP, mRNA, pDNA, or pDNA-LNP for 48 h. Supernatants were assessed for IFN-β by ELISA. N = 3 mice per strain. (B) Splenocytes from wild-type or STING knockout mice were incubated with a pool of TLR ligands, diABZI (STING agonist), or 1 μg per well of mRNA, mRNA-LNP, pDNA, or pDNA-LNP for 48 h. Supernatants were assessed for IFN-β by ELISA. N = 3 mice/strain. Supernatants were assessed for IFN-β (by ELISA), or CXCL10, CCL7, or CCL5 (by Luminex). N = 3 mice per strain (ELISA) or N = 1 mouse per strain assessed in technical replicates (Luminex studies). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 as assessed by one-way ANOVA with Tukey’s correction for multiple comparison. Results are from one experiment (A, and Luminex studies in B) or are representative of two independent experiments (IFN-β ELISA).

    Journal: Molecular Therapy Advances

    Article Title: Plasmid DNA vaccines encapsulated in lipid nanoparticles elicit STING-dependent type 1 interferon release

    doi: 10.1016/j.omta.2026.201698

    Figure Lengend Snippet: Increased IFN-β levels were not due to TLR3, 7, or 9 signaling but were at least partially mediated by STING signaling (A) Splenocytes from wild-type, TLR3 knockout (TLR3KO), TLR7KO, or TLR9KO were incubated with indicated TLR ligands or 1 μg per well of mRNA-LNP, mRNA, pDNA, or pDNA-LNP for 48 h. Supernatants were assessed for IFN-β by ELISA. N = 3 mice per strain. (B) Splenocytes from wild-type or STING knockout mice were incubated with a pool of TLR ligands, diABZI (STING agonist), or 1 μg per well of mRNA, mRNA-LNP, pDNA, or pDNA-LNP for 48 h. Supernatants were assessed for IFN-β by ELISA. N = 3 mice/strain. Supernatants were assessed for IFN-β (by ELISA), or CXCL10, CCL7, or CCL5 (by Luminex). N = 3 mice per strain (ELISA) or N = 1 mouse per strain assessed in technical replicates (Luminex studies). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 as assessed by one-way ANOVA with Tukey’s correction for multiple comparison. Results are from one experiment (A, and Luminex studies in B) or are representative of two independent experiments (IFN-β ELISA).

    Article Snippet: In some cases, cells were also incubated with 10 μg/mL TLR3 ligand (poly I:C, InVivoGen #vac-pic, San Diego, CA), 3 μg/mL TLR7 ligand (Gardiquimod, InVivoGen #tlrl-gdqs-1), 5 μM TLR9 ligand (ODN1826, Integrated DNA Technologies, San Diego, CA), 0.5 μM STING agonist (diABZI, InVivoGen #tlrl-diabzi-2; a generous gift from Dr.

    Techniques: Knock-Out, Incubation, Enzyme-linked Immunosorbent Assay, Luminex, Comparison